The therapy boosts the immune system’s strength to fight against viruses and other toxic pathogens.
An 84-year-old aged covid patient named Mohabbat Singh became the first covid patient to recover from monoclonal antibody therapy at the Medanta Hospital in Gurugram. The patient encompasses multiple morbidities was discharged from the hospital on Wednesday, 26 May.
Covid News: Patient Treated With ‘Antibody Cocktail’ In India
The therapy solely boosts the immune strength to combat viruses and toxic pathogens.
The aged patient with multiple comorbidities went home after receiving the jab at Medanta Hospital, the hospital chairman Dr. Naresh Trehan said on Wednesday.
“… We’re going to follow him. Virus multiplication drops especially in those people who have high virus load and also in those who are at high risk of severe infection,” Dr. Trehan said.
It is the same antibody cocktail that was given to former US President Donald Trump when he was tested positive for the covid-19 last year.
The therapy combines two monoclonal antibodies- REGN10933 and REGN10987, which work to inactivate the virus in question, SARS-COV-2, and block any chain reaction that helps propagate its spread in the body, thereby cutting down on reaction time.
Interestingly, the one-of-a-kind therapy, which was touted to reduce viral load and symptoms in non-hospitalized patients, is still in the early phase study in the US. Two hundred seventy-five patients have been injected with the dose, while another 1300 will be given the dose in the coming week.
The monoclonal antibodies cocktail has been used broadly in the US and Europe, Dr. Trehan told news agency ANI. “The experience shows when given in the first seven days of (Covid) infection, 70-80 percent of people who are going to be entering hospitals for treatment will not need hospitalization,” Dr. Trehan said.
Director of Pediatric Hematology-Oncology and Bone Marrow Transplant of Medanta Hospital tweeted that “Finally, monoclonal antibodies cocktail to treat Covid-19 available in the market and the first patient to get it in Medanta is an 84-year-old gentleman with Covid-19. Let’s hope it helps cure more patients with Covid-19.”
“This FDA-approved therapy showed good potency in Phase 1/2 and Phase 3 studies by lowering Covid-19 related hospitalization and death by 70 percent. Approved by the Drugs Controller General of India (DCGI), this single-dose infusion-based treatment can be provided on an outpatient or daycare basis and marks a dramatic shift in Covid-19 care in India,” it said.
The antibody is a combination of Casirivimab and Imdevimab, which is now obtainable in India is a groundbreaking treatment that will grant protection to Covid-19 positive sufferers with mild or moderate symptoms before they decline further in a state of getting hospitalization, the hospital statement said.
On Monday, drug majors Roche India and Cipla announced the launch of Roche’s Antibody Cocktail in India priced at Rs 59,750 per dose. Cipla will distribute the cocktail drug composed by Roche India.
The maximum retail price for the multi-dose pack is Rs 1,19,500, including all taxes from which each box can treat two patients. As per the report, the drug will be available through leading hospitals and COVID treatment centers.
About Monoclonal antibodies
Monoclonal antibodies are proteins cloned in the lab to mimic antibodies produced by the immune system to counter infection. They have their genesis in serum, the colorless constituent of blood that contains antibodies.
These proteins bind to an antigen, the fragment of an infectious virus in the case of SARSCoV2, and either destroy it or block its action. In the case of COVID19, there are yet no proven drugs to treat moderate or severe manifestations of the disease. Among the therapies being tested is convalescent plasma, which is a constituent of blood and recovered from those who have successfully fought the disease.
This blood contains antibodies produced within a week or two of being infected. While plasma therapy involves injecting this entire antibody soup into another sick patient, a monoclonal antibody can be made by isolating specific antibodies and multiplying them via various techniques. Isolating plasma and serum is laborious and time consuming when it must be administered to every patient.
However, since 1975, several techniques have been perfected that allow antibodies once isolated to be easily replicated. These are stored in vials and can be injected into patients.
I hope you liking our articles…
To read more News click on, Robust Story Your daily potion of inspiration.